Dexpramipexole Targets Eosinophilic Inflammation

Knopp Biosciences’ investigational, first-in-class drug, dexpramipexole, holds promise for patients with asthma and eosinophil-associated diseases. Asthma affects more than 300 million people worldwide, and is the most common noncommunicable disease among children. No cure exists for chronic asthma; most patients rely on inhaled or systemic corticosteroids to relieve coughing, wheezing and airway tightness, and to prevent asthma attacks. Many patients are unable to control their asthma with current treatments, and may prefer non-corticosteroid medications. Inhaled corticosteroids, although generally safe, have been associated with growth retardation in children and lower bone density in adults1. “There is an urgent need for alternative oral therapies to control symptoms and improve patient quality of life,” said Calman Prussin, immunologist and Vice President of Clinical and Translational Medicine at Knopp Biosciences, a privately-held drug discovery anddevelopment company based in Pittsburgh. READ FULL PDF

The release as fetched from its publisher. knoppbio.com ↗